At LambdaVision, we are focused on developing the first protein based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight due to advanced retinal degenerative diseases, including retinitis pigmentosa (RP) and age related macular degeneration (AMD). To date, the company has secured over $10M in funding in state, local, and government research funds

Skip to content